TORRENT PHARMACEUTICALS L showed marginal outperformance today. It increased by +0.62% to close at 1897.75. During the last week it increased by +0.66% and saw a maximum drawdown of -3.13% before bouncing back.
TORNTPHARM is currently in a bullish trend. The current bullish signal has generated a profit of +13.8% for TORNTPHARM's investors in the last three months.
TORNTPHARM has been outperforming the NIFTY-50 index in recent time. It showed significant underperformance (compared to the NIFTY-50 index) from 24 Aug, 2016 to 10 Nov, 2017. Over the last 3 years and 1 month, TORNTPHARM underperformed the NIFTY-50 index on 51% days.
During the last three months TORNTPHARM was mostly profitable and delivered on average +0.32% per day. It's best return during this period (of +5.12%) was on Wednesday, 12 Dec, 2018. While it's worst loss in the same period (of -4.77%) was on Friday, 2 Nov, 2018. The longest stort-term trend during this period was 6 profitable days, which started on 22 Nov, 2018 and went on till 30 Nov, 2018. This bullish trend returned +8.38% to investors.
The last 12 months saw TORNTPHARM's investors making profits in 7 months and incurring losses in 5 months. During the last year, TORNTPHARM delivered profits in more months than NIFTY-50 index. TORNTPHARM significantly outperformed NIFTY-50 index in Aug 2018, when it returned +18.59% compared to +6.56% returned by NIFTY-50 index during it's best month in the last one year - Jul 2018. TORNTPHARM and NIFTY-50 index, both had periods of 2 consecutive profitable months. It is interesting to note that both TORNTPHARM and NIFTY-50 index significantly outperform during months when quarterly/annual results are announced.
We make a living by what we get, but we make a life by what we give.
-- Winston Churchill
TORNTPHARM is currently seeing overall fall in volatility. In comparison, the NIFTY-50 index is seeing decrease in volatility. During the last three months, there was a significant fall in TORNTPHARM's volatility from 6 Nov, 2018 to 15 Jan, 2019. While there was a significant fall in the NIFTY-50 index's volatility from 31 Oct, 2018 to 5 Dec, 2018.
Advanced/professional short-term investors should note that TORNTPHARM has negative skewness in it's return distribution. This indicates that investors may need to stay invested through long periods of drawdown before expecting a recovery.
Investors trading in TORNTPHARM derivatives at this moment can consider 'Married Call' options strategy to receive better risk-adjusted returns.
TORNTPHARM has more chance of extreme outcomes than the NIFTY-50 index. Therefore, TORNTPHARM must receive a lower allocation than NIFTY-50 in your portfolio. NIFTY-50 index usually has shorter drawdown period than TORNTPHARM.
Based on your interest in TORNTPHARM you may find it interesting to know that ~MKTCAP201TO250, BAJFINANCE and ~CHEMICALS have all shown remarkable performance and qualify to be on every investor's watchlist.
... we have a small favour to ask. Help us bring the power of algorithmic trading strategies to individual investors.
All content in this article was automatically generated by algorithms. This ensures that there are no human biases in the analysis provided. This approach to investing is not new and has been around for more than three decades. Yet, it has been available to only the most affluent or elite investors leaving individual investors to trade on emotions (such as fear and greed), intuition and poor analysis from third-parties. We want to change this.
We want to empower investors with all the tools and analysis required by them to make a rational investment decision.If you found Spotalpha useful, consider making a contribution. For as little as $5 you can support our efforts and it takes less than a minute. Thank you. Contribute